Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009

J. Kristie Johnson, Gwen L. Robinson, Lisa L. Pineles, Adebola O. Ajao, LiCheng Zhao, Jennifer S. Albrecht, Anthony D. Harris, Kerri A. Thom, Jon P. Furuno
J. Kristie Johnson
aDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gwen L. Robinson
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa L. Pineles
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adebola O. Ajao
dCenter for Drug Evaluation and Research, Food and Drug Administration, Sliver Spring, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LiCheng Zhao
aDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer S. Albrecht
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony D. Harris
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerri A. Thom
bDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon P. Furuno
cDepartment of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, Oregon, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01718-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae strains are increasing in prevalence worldwide. Carbapenem antibiotics are used as a first line of therapy against ESBL-producing Enterobacteriaceae. We examined a cohort of critical care patients for gastrointestinal colonization with carbapenem-resistant ESBL-producing strains (CR-ESBL strains). We cultured samples from this cohort of patients for ESBL-producing Klebsiella spp. and Escherichia coli and then tested the first isolate from each patient for susceptibility to imipenem, doripenem, meropenem, and ertapenem. Multilocus sequence typing was performed on isolates that produced an ESBL and that were carbapenem resistant. Among all patients admitted to an intensive care unit (ICU), 4% were positive for an ESBL-producing isolate and 0.64% were positive for a CR-ESBL strain on surveillance culture. Among the first ESBL-producing E. coli and Klebsiella isolates from the patients' surveillance cultures, 11.2% were carbapenem resistant. Sequence type 14 (ST14), ST15, ST42, and ST258 were the dominant sequence types detected in this cohort of patients, with ST15 and ST258 steadily increasing in prevalence from 2006 to 2009. Patients colonized by a CR-ESBL strain were significantly more likely to receive antipseudomonal and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) therapy prior to ICU admission than patients colonized by carbapenem-susceptible ESBL-producing strains. They were also significantly more likely to have received a cephalosporin or a carbapenem antibiotic than patients colonized by carbapenem-susceptible ESBL-producing strains. In conclusion, in a cohort of patients residing in intensive care units within the United States, we found that 10% of the isolates were resistant to at least one carbapenem antibiotic. The continued emergence of carbapenem-resistant ESBL-producing strains is of significant concern, as infections due to these organisms are notoriously difficult to treat.

INTRODUCTION

Antibiotic-resistant Enterobacteriaceae infections are associated with poor clinical outcomes, including increased rates of morbidity, mortality and increased health care costs (1–3). These antibiotic-resistant bacteria, including carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum β-lactamase (ESBL)-producing bacteria, are increasing in prevalence worldwide, despite infection control efforts and antibiotic stewardship efforts (4, 5).

Carbapenem antibiotics with activity against multiple Gram-positive and Gram-negative bacterial pathogens, including members of the Enterobacteriaceae, are used as a first line of therapy against ESBL-producing Enterobacteriaceae and are often used as empirical therapy for the treatment of serious infections or as definitive therapy for antimicrobial-resistant or complex infections. As one of the few options available for the treatment of multiresistant infections, such as those caused by ESBL-producing organisms, it is imperative that we understand the emergence of and risk factors for carbapenem resistance among ESBL-producing organisms.

Gastrointestinal colonization by multidrug-resistant Gram-negative bacteria has been shown to precede clinical infection (6–8), and carbapenems are often used to treat infections cause by ESBL-producing Enterobacteriaceae strains. Furthermore, patients gastrointestinally colonized with unidentified carbapenem-resistant ESBL-producing organisms (CR-ESBL organisms) may serve as an unrecognized reservoir and facilitate the persistent transmission of these organisms to other hospitalized patients. Thus, we examined a cohort of critical care patients for gastrointestinal colonization with CR-ESBL strains.

RESULTS

Patient characteristics.During the study period there were 15,753 adult admissions to the medical intensive care unit (MICU) and the surgical intensive care unit (SICU). A total of 420 admissions (2.7%) were excluded because the patient had a surveillance culture positive for an ESBL-producing strain on a prior admission during the study period. A total of 1,372 admissions (8.7%) were excluded because a surveillance culture of a perianal swab specimen from the patient was not performed on admission.

The final sample size was 13,961 admissions. Admission and patient characteristics are displayed in Table 1. The mean age was 55.42 years (standard deviation [SD], 15.8 years), and 54.8% of the patients were male. The median length of stay in the intensive care unit (ICU) was 2.9 days (interquartile range [IQR], 1 to 6 days), 19.5% of patients died in the hospital during their admission, and 13.0% of patients died in an ICU. The most prevalent diagnoses or comorbid illnesses were chronic pulmonary disease (20.9%), diabetes (17.7%), and cancer (19.0%).

View this table:
  • View inline
  • View popup
TABLE 1

Characteristics of adult patients admitted to medical and surgical ICUsa

Four percent (557/13,961) of admissions had a surveillance culture result indicating positivity for an ESBL-producing strain upon ICU admission; 1.8% (247/13,961) of all admissions had a negative culture result on admission but a subsequent surveillance culture result indicating positivity for an ESBL-producing strain result during their ICU stay, indicating the possible acquisition of the ESBL-producing strain during their ICU stay. One percent (144/13,961) of the patients in the cohort had a positive clinical culture result for Escherichia coli or Klebsiella spp. at any point during their admission; 77 (53.5%) of these patients were positive 48 h or more after admission to an ICU. Thirty percent (43/144) of the patients with a positive clinical culture result had a prior surveillance culture result positive for an E. coli or Klebsiella species producing an ESBL.

The prevalence of colonization with a CR-ESBL strain was 0.64% (90/13,961) among all ICU admissions, and among the first ESBL-producing E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca isolates from the patients' surveillance cultures, the prevalence of carbapenem resistance was 11.2% (90/804). The differences between patients colonized with a CR-ESBL strain and patients colonized with a carbapenem-susceptible ESBL-producing strain are displayed in Table 2. Patients colonized with a CR-ESBL strain had a significantly longer median length of stay in an ICU. There were no other significant differences in demographic characteristics, clinical characteristics, or comorbid illnesses between patients colonized with CR-ESBL strains and patients colonized with carbapenem-susceptible ESBL-producing strains. There were, however, several significant differences between these two groups with respect to their antibiotic exposures before their ICU admission. Patients colonized by CR-ESBL strains were significantly more likely to receive any antimicrobial therapy and, specifically, were more likely to receive antipseudomonal, anti-methicillin-resistant Staphylococcus aureus (anti-MRSA), or vancomycin therapy prior to ICU admission than patients colonized by carbapenem-susceptible ESBL-producing strains. They were also significantly more likely to have received a cephalosporin or a carbapenem antibiotic than patients colonized by carbapenem-susceptible ESBL-producing strains.

View this table:
  • View inline
  • View popup
TABLE 2

Characteristics of patients positive for CR-ESBL strains compared to those of patients positive for carbapenem-susceptible ESBL-producing isolatesa

Microbiological characteristics.The prevalence of ESBL-producing E. coli and Klebsiella species in our cohort of ICU patients was 5.8% (804/13,961). From these 804 patients, we detected 891 isolates; 39% (345/891) were E. coli isolates and 61% (546/891) were Klebsiella spp. Data by year are shown in Table 3, which shows a large increase in the prevalence of ESBL-producing strains from 2005 to 2006. Of note, 57 patients (7.1%) were colonized with both an ESBL-producing E. coli strain and an ESBL-producing Klebsiella sp.

View this table:
  • View inline
  • View popup
TABLE 3

Number of ESBL-producing E. coli and Klebsiella species isolates from 2001 to 2009

The median MICs for each carbapenem antibiotic by year are shown in Fig. 1 and 2. For both E. coli and Klebsiella spp., the median MICs for all antibiotics except meropenem increased in 2005, which was about the same time that an increase in the prevalence of colonization with ESBL-producing strains was seen. For meropenem, a decrease in the MICs for both E. coli and Klebsiella spp. was noted beginning in 2005; however, the MICs for both groups of isolates began increasing in 2007 and by 2009 the MICs were similar to data reported for 2001 to 2004.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Median carbapenem MIC per year for ESBL-producing Escherichia coli isolates (n = 345).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Median carbapenem MIC per year for ESBL-producing Klebsiella spp. (n = 546).

Of the 804 patients, 90 patients (11.2%) were colonized by 91 isolates determined to be CR-ESBL strains, 22 (24%) were colonized by E. coli strains, and 69 (76%) were colonized by Klebsiella spp. One E. coli isolate and eight K. pneumoniae isolates were resistant to all four carbapenem antibiotics (Table 4), with more than half of these isolates being collected in 2009. In addition, 26 K. pneumoniae isolates and 7 E. coli isolates had intermediate resistance to ertapenem but were susceptible to the other three carbapenems. Of the 91 CR-ESBL isolates, 46 (50.5%) were positive for blaKPC (17 were E. coli, 28 were K. pneumoniae, and 1 was K. oxytoca).

View this table:
  • View inline
  • View popup
TABLE 4

Characteristics of CR-ESBL strains resistant to all four carbapenems

Multilocus sequence typing (MLST) results are displayed for CR-ESBL K. pneumoniae and E. coli isolates by year in Tables 5 and 6, respectively. For K. pneumoniae isolates, sequence type 14 (ST14), ST15, ST42, and ST258 were seen to be the dominant sequence types (STs). The data showed that the ST258 strain was first detected in 2006 and that its incidence increased steadily each year until 2009, when 12 resistant ST258 isolates were detected in a 6-month period. Similar results were observed with ST15. Currently, there is not a standard MLST method for K. oxytoca; therefore, pulsed-field gel electrophoresis (PFGE) was performed. In contrast to the findings for K. pneumoniae, the PFGE results suggest that unrelated CR-ESBL K. oxytoca strains were isolated in 2008. Among the E. coli isolates, ST131, ST167, and ST393 were the dominant sequence types. Unlike the ST258 isolates of K. pneumoniae, the data do not suggest a dominant clone of E. coli that established itself from year to year.

View this table:
  • View inline
  • View popup
TABLE 5

Distribution of MLST STs among Klebsiella pneumoniae isolates intermediate or resistant to carbapenems from 2001 to 2009

View this table:
  • View inline
  • View popup
TABLE 6

Distribution of MLST STs among E. coli isolates intermediate or resistant to carbapenems from 2001 to 2009

DISCUSSION

In the large cohort of ESBL-producing E. coli and Klebsiella spp. isolated from surveillance cultures of perianal swab specimens from critical care patients from 2001 to 2009 evaluated in the present study, we observed that approximately 10% of isolates were resistant to at least one carbapenem antibiotic. The median MICs of all carbapenems except meropenem appeared to increase among Klebsiella spp. and E. coli during the study period, correlating with the increase in the incidence of CR-ESBL strains. Data on health care-associated clinical Klebsiella and E. coli infections reported to the CDC in 2009 and 2010 showed the rates of carbapenem resistance to be 12.8% and 1.9%, respectively (9). These numbers are slightly higher for Klebsiella spp. and lower for E. coli than the numbers that we observed in our study; however, we studied only isolates known to produce ESBLs.

ESBL-producing organisms are prevalent worldwide, and their incidence appears to be increasing (4, 5). Infections due to these organisms, which are associated with poor outcomes, pose a significant challenge, in that multidrug resistance leads to limitations in the number of effective antibiotics that are available. Carbapenem antibiotics are considered the drug of choice for treating infections caused by ESBL-producing organisms. Carbapenem resistance among ESBL-producing strains further compounds the challenge of effective treatment, often leaving clinicians to decide between agents with reduced efficacy and agents with increased toxicity, such as polymyxins or tigecycline. The relatively high rates of carbapenem-resistant ESBL-producing organisms seen in this study are thus of great concern, and research needs to be done in the future to identify strategies aimed at preventing their further emergence. CR-ESBL strains should be considered along with other multidrug-resistant organisms, including extremely drug-resistant (XDR) Acinetobacter baumannii and (XDR) Pseudomonas aeruginosa strains.

Given the high acuity of illness in this population, many patients received antibiotic therapy prior to ICU admission, and several of these antibiotic exposures were associated with carbapenem resistance. Patients colonized by CR-ESBL strains were significantly more likely to receive antipseudomonal and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) therapy prior to ICU admission than patients colonized by carbapenem-susceptible ESBL-producing strains. They were also significantly more likely to have received a cephalosporin or carbapenem antibiotic than patients colonized by carbapenem-susceptible ESBL-producing strains. Molecular data for the CR-ESBL strains suggest no sporadic strains for E. coli, but among the K. pneumoniae isolates, numerous identical strains were detected in a single year or, once they were detected, became endemic within the ICUs. As such, molecular data suggest that CR-ESBL E. coli and K. oxytoca strains are more likely to be due to antibiotic selective pressure and CR-ESBL K. pneumoniae strains are more likely to be due to patient-to-patient transmission.

This study had limitations. First, isolates were from one tertiary care hospital, so the generalizability to other hospitals might be limited. Specifically, the resistance patterns detected in the hospital that we studied may not be comparable to those detected in other hospitals in other regions of the United States. We also included only carbapenem-resistant isolates that were ESBL positive. The prevalence of carbapenem-resistant isolates and the risk factors for patients who acquire carbapenem resistance could have been different if we had studied carbapenem resistance in all Enterobacteriaceae and not just those that were ESBL positive. The use of ceftazidime in the screening agar may have caused the CTX-M family of β-lactamases to have been missed. However, in previous studies that used this screening agar, we were able to detect bacteria harboring blaCTX-M (10). Lastly, even though we identified several antimicrobial exposures to be risk factors for carbapenem resistance, our dichotomous classification of antimicrobial exposures may have underestimated the magnitude of these and other antimicrobial associations (11).

In conclusion, this is the first study, to our knowledge, to examine the rate of colonization with carbapenem-resistant ESBL-producing E. coli and K. pneumoniae isolates in a cohort of patients residing in intensive care units within the United States, and we found that 10% of isolates were resistant to at least one carbapenem antibiotic. The continued emergence of carbapenem-resistant ESBL strains is of significant concern, as infections due to these organisms are notoriously difficult to treat.

MATERIALS AND METHODS

Study population.This study utilized surveillance cultures of perianal swab specimens collected from a cohort of adult (age, ≥18 years) patients admitted to the medical and surgical intensive care units of the University of Maryland Medical Center between 1 September 2001 and 30 June 2009. During the study period, the MICU was a 10-bed unit with private rooms that became a 29-bed unit with private rooms in April 2006, and the SICU was a 19-bed unit with private rooms. Prior to study commencement, the University of Maryland, Baltimore, Institutional Review Board approved this study.

Perianal swab specimens for culture were obtained from the patients at ICU admission (within 48 h of admission), weekly, and at the time of ICU discharge according to University of Maryland Medical Center Department of Infection Prevention surveillance practices. Samples for culture were obtained using Staplex II swabs (Staplex, Etobiocoke, Ontario, Canada) and frozen in tryptic soy broth with 15% glycerol using validated methods (12). The rate of compliance with the collection of perianal swab specimens for culture was approximately 90%. For patients who had multiple admissions, each admission could be entered into the cohort until the patient had a culture result indicating positivity for an ESBL-producing organism, after which data on subsequent admissions and associated patient data were excluded from the analysis. Patients were excluded from the study if a specimen for culture was not collected within the first 48 h of admission or if only one swab specimen was collected during their ICU stay.

The characteristics of the eligible patients were obtained using a relational database that contains patients' administrative, pharmaceutical, and microbiological data. These data were validated in previous studies and have positive and negative predictive values in excess of 99% compared to those from paper medical records (13–17).

Bacterial identification.Perianal swab specimens were plated on MacConkey agar with 1 μg/μl ceftazidime; lactose-fermenting organisms were identified to be Escherichia coli and Klebsiella spp. using standard protocols. Isolates that harbored ESBLs were detected by the use of the ESBL confirmation test according to Clinical and Laboratory Standards Institute (CLSI) guidelines (18) described in a previous study (10). Carbapenem MICs were measured using an Etest (bioMérieux, Durham, NC) for imipenem, doripenem, meropenem, and ertapenem for the first Klebsiella oxytoca, K. pneumoniae, and E. coli isolate from each patient that was confirmed to produce an ESBL. Susceptibility testing was performed following CLSI guidelines (18). Isolates with intermediate resistance or resistance to any of the four carbapenem antibiotics to which the susceptibilities of the isolates were tested were defined to be carbapenem resistant.

Molecular typing.Multilocus sequence typing was performed on any ESBL-producing E. coli and Klebsiella pneumoniae isolates that were nonsusceptible to a carbapenem. MLST was performed according to previously published protocols (19, 20). The nucleotide sequences of both strands were determined using published primers and compared to existing sequences in the MLST databases (http://mlst.ucc.ie/mlst ; http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html ) for assignment of allelic numbers. The isolates were assigned a sequence type (ST) number according to their allelic profiles.

Pulsed-field gel electrophoresis (PFGE) was performed on the K. oxytoca isolates following a previously published protocol (21). Interpretation of the results was performed using BioNumerics software (Applied Math, Sint-Martens-Latem, Belgium). A dendrogram comparing the isolates was constructed using the Dice coefficient and unweighted pair group method with arithmetic mean (UPGMA) with a position tolerance of 1. Isolates with >80% similarity were considered similar according to the criteria of Tenover et al. (22).

Molecular detection of KPC.ESBL-producing E. coli and Klebsiella isolates that were resistant to carbapenems (CR-ESBL isolates) were further tested for the detection of the Klebsiella pneumoniae carbapenemase (KPC) gene following a previous published protocol (23).

Statistical analysis.Only the first E. coli, K. pneumoniae, or K. oxytoca isolate from each patient that produced an ESBL was used in this study. All data were analyzed using SAS statistical software, version 9.2.1 (SAS Institute, Cary, NC). Univariable analysis utilized means and frequencies to assess distributions. Demographic and antibiotic exposures between patients colonized with ESBL-positive isolates with and without carbapenem resistance were compared using appropriate methods for continuous and categorical variables.

ACKNOWLEDGMENTS

This work was funded by an unrestricted research grant from Merck Pharmaceuticals. This research was also supported by National Institutes of Health grants 1K01AI071015 to J.P.F., R01A1060859 and 5K24AI079040 to A.D.H., IK12RR023250 to J.K.J., and IK23AI082450-03 to K.A.T.

FOOTNOTES

    • Received 8 August 2016.
    • Returned for modification 13 September 2016.
    • Accepted 10 January 2017.
    • Accepted manuscript posted online 6 February 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Carlet J,
    2. Jarlier V,
    3. Harbarth S,
    4. Voss A,
    5. Goossens H,
    6. Pittet D
    ,participants of the 3rd World Healthcare-Associated Infections Forum. 2012. Ready for a world without antibiotics? The Pensieres Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control1:11. doi:10.1186/2047-2994-1-11.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cosgrove SE
    . 2006. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis42(Suppl 2):S82–S89. doi:10.1086/499406.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Slama TG
    . 2008. Gram-negative antibiotic resistance: there is a price to pay. Crit Care12(Suppl 4):S4. doi:10.1186/cc6820.
    OpenUrlCrossRef
  4. 4.↵
    1. Carbonne A,
    2. Arnaud I,
    3. Maugat S,
    4. Marty N,
    5. Dumartin C,
    6. Bertrand X,
    7. Bajolet O,
    8. Savey A,
    9. Fosse T,
    10. Eveillard M,
    11. Senechal H,
    12. Coignard B,
    13. Astagneau P,
    14. Jarlier V
    ,MDRB Surveillance National Steering Group (BMR-Raisin). 2013. National multidrug-resistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother68:954–959. doi:10.1093/jac/dks464.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tacconelli E,
    2. Cataldo MA,
    3. Dancer SJ,
    4. De Angelis G,
    5. Falcone M,
    6. Frank U,
    7. Kahlmeter G,
    8. Pan A,
    9. Petrosillo N,
    10. Rodriguez-Bano J,
    11. Singh N,
    12. Venditti M,
    13. Yokoe DS,
    14. Cookson B
    ,European Society of Clinical Microbiology. 2014. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect20(Suppl 1):S1–S55. doi:10.1111/1469-0691.12427.
    OpenUrlCrossRef
  6. 6.↵
    1. Donskey CJ
    . 2006. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis43(Suppl 2):S62–S69. doi:10.1086/504481.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hess A,
    2. Kleinberg M,
    3. Sorkin J,
    4. Netzer G,
    5. Johnson J,
    6. Shardell M,
    7. Thom K,
    8. Harris A,
    9. Roghmann M
    . 2014. Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients. Diagn Microbiol Infect Dis79:73–76. doi:10.1016/j.diagmicrobio.2014.01.022.
    OpenUrlCrossRef
  8. 8.↵
    1. Wingard JR,
    2. Dick J,
    3. Charache P,
    4. Saral R
    . 1986. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob Agents Chemother30:435–439. doi:10.1128/AAC.30.3.435.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Sievert D,
    2. Ricks P,
    3. Edwards J,
    4. Schneider A,
    5. Patel J,
    6. Srinivasan A,
    7. Kallen A,
    8. Limbago B,
    9. Fridkin S
    . 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol34:1–14. doi:10.1086/668770.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ajao A,
    2. Johnson JK,
    3. Harris A,
    4. Zhan M,
    5. McGregor J,
    6. Thom K,
    7. Furuno J
    . 2013. Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit. Infect Control Hosp Epidemiol34:453–458. doi:10.1086/670216.
    OpenUrlCrossRef
  11. 11.↵
    1. Hyle EP,
    2. Gasink LB,
    3. Linkin DR,
    4. Bilker WB,
    5. Lautenbach E
    . 2007. Use of different thresholds of prior antimicrobial use in defining exposure: impact on the association between antimicrobial use and antimicrobial resistance. J Infect55:414–418. doi:10.1016/j.jinf.2007.07.005.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Green HP,
    2. Johnson JA,
    3. Furuno JP,
    4. Strauss SM,
    5. Perencevich EN,
    6. Lautenbach E,
    7. Lee D,
    8. Harris AD
    . 2007. Impact of freezing on the future utility of archived surveillance culture specimens. Infect Control Hosp Epidemiol28:886–888. doi:10.1086/518843.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. McGregor JC,
    2. Kim PW,
    3. Perencevich EN,
    4. Bradham DD,
    5. Furuno JP,
    6. Kaye KS,
    7. Fink JC,
    8. Langenberg P,
    9. Roghmann MC,
    10. Harris AD
    . 2005. Utility of the chronic disease score and Charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol161:483–493. doi:10.1093/aje/kwi068.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. McGregor JC,
    2. Perencevich EN,
    3. Furuno JP,
    4. Langenberg P,
    5. Flannery K,
    6. Zhu J,
    7. Fink JC,
    8. Bradham DD,
    9. Harris AD
    . 2006. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol59:1266–1273. doi:10.1016/j.jclinepi.2006.01.016.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. McGregor JC,
    2. Rich SE,
    3. Harris AD,
    4. Perencevich EN,
    5. Osih R,
    6. Lodise TP Jr,
    7. Miller RR,
    8. Furuno JP
    . 2007. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis45:329–337. doi:10.1086/519283.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Osih RB,
    2. McGregor JC,
    3. Rich SE,
    4. Moore AC,
    5. Furuno JP,
    6. Perencevich EN,
    7. Harris AD
    . 2007. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother51:839–844. doi:10.1128/AAC.00901-06.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Harris AD,
    2. Johnson JK,
    3. Thom KA,
    4. Morgan DJ,
    5. McGregor JC,
    6. Ajao AO,
    7. Moore AC,
    8. Comer AC,
    9. Furuno JP
    . 2011. Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting. Infect Control Hosp Epidemiol32:719–722. doi:10.1086/660763.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial disk susceptibility testing; twenty-second informational supplement. Clinical and Laboratory Standards Institute,Wayne, PA.
  19. 19.↵
    1. Diancourt L,
    2. Passet V,
    3. Verhoef J,
    4. Grimont PA,
    5. Brisse S
    . 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol43:4178–4182. doi:10.1128/JCM.43.8.4178-4182.2005.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Wirth T,
    2. Falush D,
    3. Lan R,
    4. Colles F,
    5. Mensa P,
    6. Wieler LH,
    7. Karch H,
    8. Reeves PR,
    9. Maiden MC,
    10. Ochman H,
    11. Achtman M
    . 2006. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol60:1136–1151. doi:10.1111/j.1365-2958.2006.05172.x.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Harris AD,
    2. Perencevich EN,
    3. Johnson JK,
    4. Paterson DL,
    5. Morris JG,
    6. Strauss SM,
    7. Johnson JA
    . 2007. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis45:1347–1350. doi:10.1086/522657.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Tenover FC,
    2. Arbeit RD,
    3. Goering RV
    . 1997. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol18:426–439.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Rasheed JK,
    2. Biddle JW,
    3. Anderson KF,
    4. Washer L,
    5. Chenoweth C,
    6. Perrin J,
    7. Newton DW,
    8. Patel JB
    . 2008. Detection of the Klebsiella pneumoniae carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J Clin Microbiol46:2066–2069. doi:10.1128/JCM.02038-07.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009
J. Kristie Johnson, Gwen L. Robinson, Lisa L. Pineles, Adebola O. Ajao, LiCheng Zhao, Jennifer S. Albrecht, Anthony D. Harris, Kerri A. Thom, Jon P. Furuno
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e01718-16; DOI: 10.1128/AAC.01718-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009
J. Kristie Johnson, Gwen L. Robinson, Lisa L. Pineles, Adebola O. Ajao, LiCheng Zhao, Jennifer S. Albrecht, Anthony D. Harris, Kerri A. Thom, Jon P. Furuno
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e01718-16; DOI: 10.1128/AAC.01718-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Escherichia coli
Escherichia coli Infections
Klebsiella
Klebsiella Infections
beta-lactam resistance
beta-lactamases
ESBL
MLST
carbapenem resistant

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596